

Supplement Table 1: Pre and Post Treatment Study Measures for Overall PTSD, Nightmare, and Sleep Quality Scores in Prazosin and Placebo Groups

Outcome: Overall PTSD Score									
Measure	StudyName	Prazosin (n)	Prazosin Pre (Mean±SD)	Prazosin Post (Mean±SD)	Prazosin Pre Mean-Post Mean	Placebo (n)	Placebo Pre (Mean±SD)	Placebo Post (Mean±SD)	Placebo Pre Mean-Post Mean
CAPS - total	Raskind 2003	10	79.1±17	57.3±32.3	46.8	10	83.6±17.6	86.5±30	-2.9
CAPS - total	Raskind 2007	17	76±22	63±20	56	17	78±18	71±22	7
PCL-C (PTSD checklist-Civilian)	Taylor 2008	13	58±13	51±14	44	13	56±16	55±15	1
PCL symptom measures	Germain 2012	17	43.9±17.3	33.3±16.4	27.5	14	35±14.1	35.1±14.3	-0.1
CAPS - total	Raskind 2013	32	77.3±22.7	52.2±23.2	54.1	35	85.7±22.3	71.9±23.1	13.8
CAPS total score	Raskind 2018	135	80.7±15.5	68.9±19.9	60.8	136	81.9±17.1	68.8±23.9	13.1
Outcome: Nightmares									
Measure	StudyName	Prazosin (n)	Prazosin Pre (Mean±SD)	Prazosin Post (Mean±SD)	Prazosin Pre Mean-Post Mean	Placebo (n)	Placebo Pre (Mean±SD)	Placebo Post (Mean±SD)	Placebo Pre Mean-Post Mean
CAPS - recurrent distressing asleep	Raskind 2003	10	6.9±0.9	3.6±2.8	4.1	10	7.1±0.9	6.7±1.6	0.4
Nightmare aggregate	Raskind 2007	17	6.5±1	3.2±2.6	3.9	17	6.1±1	5.2±2.2	0.9
CAPS recurrent distressing dreams-item 2	Taylor 2008	13	4.8±1.7	3.3±2.3	2.5	13	3.9±2.3	3.9±1.9	0
Sleep diary measure - nightmare frequency	Germain 2012	15	1±1.1	0.3±0.8	0.2	14	0.4±1.1	0.5±1.1	-0.1
CAPS nightmare item	Raskind 2013	32	6±1.7	2.9±1.8	4.2	35	6.6±1.7	5.4±1.7	1.2
CAPS item B2 score	Raskind 2018	135	6.3±0.9	4.4±2.1	4.2	136	6.3±0.9	4.6±2.3	1.7
Outcome: Sleep Quality									
Measure	StudyName	Prazosin (n)	Prazosin Pre (Mean±SD)	Prazosin Post (Mean±SD)	Prazosin Pre Mean-Post Mean	Placebo (n)	Placebo Pre (Mean±SD)	Placebo Post (Mean±SD)	Placebo Pre Mean-Post Mean
PSQI - total score	Raskind 2003	10	7.4±1.3	4±2.3	5.1	10	7.3±0.9	7.1±1.9	0.2
PSQI - total score	Raskind 2007	17	13.5±4.2	9.7±3.9	9.6	17	13.4±2.7	12.6±4.1	0.8
CAPS Item 13	Taylor 2008	13	6±1	4.8±1.8	4.2	13	6.1±0.8	5.6±1.4	0.5
PSQI - total score	Germain 2012	14	11.6±3.1	7.6±2.9	8.7	13	10.5±3.6	8.9±3.4	1.6
PSQI	Raskind 2013	32	14.1±3.7	8.5±3.9	10.2	35	14.5±3.6	11.6±3.9	2.9
PSQI score	Raskind 2018	135	14.4±3.3	12.1±4.4	10	136	14.7±3.5	12.3±4.3	2.4

Supplement Table 2: Univariate Meta Regression Across Study Outcomes

Meta-Regression Variables	Exponentiated Effect Estimate exp (β)	P-value
Sleep Quality		
Age (mean, year)	1.00	(p=0.82)
Gender (% male)	1.00	(p=0.99)
Duration (weeks)	0.96	(p=0.67)
Dosage (mg/day)	1.05	(p=0.65)
Nightmares		
Age (mean, year)	1.04	(p=0.16)
Gender (% male)	1.00	(p=0.79)
Duration (weeks)	0.95	(p=0.53)
Dosage (mg/day)	1.03	(p=0.70)
Overall PTSD		
Age (mean, year)	1.03	(p=0.93)
Gender (% male)	1.00	(p=0.96)
Duration (weeks)	0.99	(p=0.99)
Dosage (mg/day)	1.04	(p=0.94)